{"id":"W4308254443","doi":"10.1007/s41669-022-00375-x","title":"A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"ABB (Canada); Foothills Medical Centre","funders":"AbbVie","keywords":"Obinutuzumab; Venetoclax; Medicine; Chlorambucil; Rituximab; Bendamustine; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; Population; Ofatumumab; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004650886,0.001602031,0.001859296,0.001636805,0.00102297,0.002501501,0.002788812,0.001864893,0.004978959],"category_scores_gemma":[0.01278839,0.001052964,0.002857338,0.002023801,0.001213031,0.0008750095,0.001260378,0.00202081,0.0001771938],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.04434488,"about_ca_system_score_gemma":0.02427574,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8094695,"about_ca_topic_score_gemma":0.605514,"domain_scores_codex":[0.9977672,0.00111215,0.00005525137,0.0002068017,0.0002442641,0.0006141916],"domain_scores_gemma":[0.9916527,0.005813873,0.0006572704,0.0001522222,0.00103106,0.0006928768],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.001097667,0.0001120113,0.00402315,0.0001597471,0.0002891443,0.000164362,0.00004067596,0.9851151,0.0001267612,0.004556266,0.001115313,0.003199698],"study_design_scores_gemma":[0.0007796027,0.0005722719,0.007774225,0.0001336612,0.0007296178,0.000107636,0.0002039095,0.9845827,0.0001792095,0.00275281,0.002118879,0.00006544513],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9360598,0.00634884,0.01259506,0.004386454,0.0000941679,0.001587059,0.01639446,0.0001292111,0.02240487],"genre_scores_gemma":[0.9917318,0.001073095,0.002328823,0.0002035656,0.00001756531,0.0002495851,0.00191284,0.00001226754,0.002470415],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1905305,"threshold_uncertainty_score":0.3833051,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04922340262774139,"score_gpt":0.3689317120683685,"score_spread":0.3197083094406271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}